Vilnius enzyme designer Biomatter raises $18m Series A led by Astanor to build a lab and grow in the US


Lithuanian AI enzyme designer Biomatter has raised an $18m Series A led by Astanor to open a 2,000 m² Vilnius facility in 2027, expand its sales team and grow in the US.
Biomatter (biomatter.ai) is a Vilnius-based protein design company founded in 2018 (formerly Biomatter Designs). Its Intelligent Architecture platform combines generative AI with physics-based modelling to design enzymes starting from the target chemical reaction.
- Series A: $18M (company figure), led by Astanor, Nov 2026. Funds a 2,000 m² Vilnius facility opening in 2027, a larger sales team and US growth.
- Seed: €6.5M, Aug 2024, led by Inventure and UVC Partners.
- Customers reported: AstraZeneca, BASF, Sanofi; worked with Thermo Fisher on SuperScript V reverse transcriptase.
- Joined AstraZeneca BioVentureHub.
- Founders: Laurynas Karpus (Co-founder & CEO), Vykintas Jauniškis (Co-founder), Irmantas Rokaitis (Co-founder).
What did you think of this story?
Written by
Sandra J. Barbara
60 stories on European Startup Insider
Have a story like this? Pitch it to us.
We publish founder profiles, company news and practical guides from across Europe.
More stories like this
Helsinki's Stoa raises €3.5m pre-seed from Lifeline to take its construction-site AI to data centre builds
Stoa, which turns drawings, schedules and site reports into answers for construction crews, raised €3.5m led by Lifeline Ventures and will chase data centre projects in the Nordics, UK and US.







